Figure 5. Inhibition of protein synthesis by dsRNA and inhibition of IL-1ß processing by MG-132.

A) BMDM were treated with or without 4 h of LPS priming, as indicated. Cells were then rinsed in fresh medium and treated with either LipofectAMINE 2000 or LipofectAMINE 2000-poly I:C complex for 4 h, in the presence or absence of 30 µM MG-132, as indicated. Cell lysates (cell) or media (medium) samples were subjected to immunoblotting with the antibodies indicated. B) BMDM were treated with either LipofectAMINE 2000 alone or with LipofectAMINE 2000-dsRNA complex for the times indicated. Fifteen minutes before each time-point, 1 µCi of [³H]-leucine was added, and leucine incorporation was terminated by trichloroacetic acid. Each treatment was conducted in triplicate wells, and values are shown as mean ± S.D. Percent incorporation of [³H]-leucine at each point was calculated as the [³H]-leucine incorporated into cells exposed to LipofectAMINE 2000-dsRNA complex/[³H]-leucine incorporated into cells exposed to LipofectAMINE 2000 alone×100.